PHILADELPHIA, Feb. 24, 2021 /PRNewswire/ -- Enterin,
Inc., a privately held, Philadelphia-based, clinical-stage
biopharmaceutical company pioneering novel treatments for
neurodegenerative diseases, announces the appointment of
Katherine Wolf as Chief Financial
Officer. Ms. Wolf brings 30 years of health care industry
experience in capital raising, business development, and strategy,
during which she has executed financing, advisory, and M&A
transactions worth approximately $24
billion.
"We are thrilled that Katherine is joining the Enterin
team. She has deep experience as a healthcare CFO, advisor,
and investment banker. Her background in capital markets, her
reputation among the financial community, and her experience as a
public company CFO will help Enterin as we position the company for
the next phase of growth," said David
McCullough, Enterin's CEO. Enterin's Chairman,
Jay Brammer, added "Katherine will
make an excellent business partner to David as we move Enterin's
compounds through the clinic."
"I am excited to join a company with such great potential," said
Ms. Wolf. "I believe Enterin's novel approach toward
neurodegenerative diseases is truly groundbreaking, and I am
looking forward to advancing the company's mission and
strategy."
Before joining Enterin, Ms. Wolf was Managing Member of health
care consultancy KLW Advisors where she worked as an advisor and
Acting CFO to various clients, prior to which she served as Partner
and Senior Advisor at Ondra Partners, a boutique investment
bank. Previously, her positions included CEO & Co-Founder
of health care consultancy Rocket Science, and CFO & EVP of
Vision-Sciences, a publicly-traded medical technology
company. Additionally, Ms. Wolf has extensive prior health
care investment banking experience at both global and boutique
investment banks, including HSBC Securities, Bear Stearns and SG
Cowen. Ms. Wolf received an MBA from Harvard
Business School and a BA from Williams
College.
About Enterin Inc.
Enterin Inc. is the first company to develop novel compounds
that repair the dysfunctional gut-brain axis in patients with
neurodegenerative diseases. Enterin Inc. is pioneering the medical
community's understanding of the link between infections,
dysfunction of the enteric nervous system (ENS) of the gut and the
early onset and chronic progression of neurodegenerative disease.
The lead compound, ENT-01, displaces membrane-bound alpha-synuclein
(αS) aggregates from nerve cells in the ENS and improves neural
signaling between the gut and the brain in preclinical models of
Parkinson's disease. Enterin Inc. is now progressing ENT-01 through
clinical trials in an attempt to reverse the neurologic symptoms of
Parkinson's disease.
For more information, please visit www.enterininc.com.
Contact
Enterin Inc.
info@enterininc.com
Related Images
enterin-logo.png
Enterin Logo
Enterin Logo
View original content to download
multimedia:http://www.prnewswire.com/news-releases/enterin-announces-appointment-of-chief-financial-officer-301234867.html
SOURCE Enterin Inc.